Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

sus temsirolimus in relapsed or refractory  MCL patients, RAY (MCL3001). This trial is a randomized, multi-center, open-label trial of ibrutinib as a mono-therapy versus temsirolimus in relapsed or refractory MCL patients who received at least one prior rituximab-containing chemotherapy regimen. The primary endpoint of the study is progression free survival when compared to temsirolimus. This global study, conducted by Janssen outside the US, is open and Janssen plans to enroll 280 patients.
  • Phase III study of ibrutinib in combination with bendamustine and rituximab in patients with newly diagnosed MCL, SHINE (MCL3002). This trial is a randomized, multi-center, double-blinded, placebo-controlled trial of ibrutinib plus bendamustine and rituximab versus placebo plus bendamustine and rituximab in subjects with newly diagnosed MCL. The primary endpoint of the study is progression free survival when compared to bendamustine and rituximab. Janssen plans to enroll 520 patients in this study.
  • Phase II study of ibrutinib in patients with mantle cell lymphoma who progress after bortezomib therapy, SPARK (MCL2001). This is a single-arm, multi-center trial of ibrutinib as a monotherapy in relapsed or refractory MCL patients who received at least one prior rituximab-containing chemotherapy regimen and who progressed after bortezomib therapy. The primary endpoint of the study is overall response rate. This global study, conducted by Janssen, is open and Janssen plans to enroll 110 patients worldwide.
  • Phase II study of ibrutinib in patients with mantle cell lymphoma who progress after bortezomib therapy, SPARK (MCL2001). This is a single-arm, multi-center trial of ibrutinib as a monotherapy in relapsed or refractory MCL patients who received at least one prior rituximab-containing chemotherapy regimen and who progressed after bortezomib therapy. The primary endpoint of the study is overall response rate. This global study, conducted by Janssen,
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/30/2014)... Chicago, Illinois (PRWEB) October 30, 2014 ... Regenerative and Cellular Medicine Showcase in Chicago, leading ... and Orthopedic Surgeon, Dr. Wade McKenna presented talks ... Effectiveness and Orthopedic Surgical Applications For Stem Cells. ... of amniotic membrane and the properties of AlphaGEMS ...
    (Date:10/30/2014)... 30, 2014 Whitehouse Laboratories has formally ... Stability Testing and Package Test Capacity. Responding to growing ... a dramatic increase in environmental chamber storage space that ... and aging samples to be securely held on site ... capital expenditure has already taken place with the recent ...
    (Date:10/30/2014)... BASKING RIDGE, N.J. , Oct. 30, 2014 /PRNewswire/ ... announced that it will hold a conference call and ... 8:30 a.m. EST to discuss its third quarter 2014 ... access the conference call by dialing (888) 347-1165 for ... conference call will be webcast live under the investor ...
    (Date:10/27/2014)... 27, 2014 The Italian ... exhibit and sell its artificial "lower limb", after ... patent.      (Photo: http://photos.prnewswire.com/prnh/20141027/713097 ... fighting, the definitive judgement has arrived: Roadrunnerfoot, the ... and accessible hi-tech prostheses with composite materials, has ...
    Breaking Biology Technology:Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Regado Biosciences to Provide Third Quarter 2014 Financial Results 2Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2
    ... Spherix Incorporated (NASDAQ: SPEX ) – ... syndrome and atherosclerosis, and provider of technical and regulatory ... today announced that it has entered into definitive agreements ... stock and warrants to purchase shares of its common ...
    ... +49(0)69-2222-34066 France: +33(0)1-70-48-01-63 U.K.: +44(0)20-7660-0009 ... is 5634610; to view the webcast, log onto: ... March 13, 2012 - Annual press conference in Goettingen, Germany ... Germany April 24, 2012 - Publication of first-quarter ...
    ... A relatively fast, easy and inexpensive technique for ... self-assemble into one-, two- and even three-dimensional macroscopic ... researchers with the U.S. Department of Energy (DOE),s ... should enable more effective use of nanorods in ...
    Cached Biology Technology:Spherix Announces Registered Direct Offering of $1.15 Million 2Spherix Announces Registered Direct Offering of $1.15 Million 3Preliminary Figures for 2011: Sartorius Grows at Double-Digit Rates and Boosts Operating Earnings by More Than 30% 2Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks 2Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks 3Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks 4
    (Date:10/31/2014)... In the war against Ebola one important hurdle has ... Researchers at the University of North Carolina at Chapel ... of mice that can be infected with Ebola and ... work, published in the current issue of Science ... and vaccines, which are desperately needed to curb the ...
    (Date:10/31/2014)...  HITLAB SM , a healthcare innovation and ... HITLAB Innovators Summit SM on December 1, ... partner with the Clinton Foundation,s Health Matters Initiative, ... Business School Alumni Club of New ... Operations Research, bringing together leaders in healthcare and ...
    (Date:10/30/2014)... in German . ... fellow humans to behave socially? This is one of ... theory. Previous studies assumed that it is almost impossible ... the Max Planck Institute for Evolutionary Biology have now ... on the cooperative behaviour of others. However, the possibilities ...
    Breaking Biology News(10 mins):Improved mouse model will accelerate research on potential Ebola vaccines, treatments 2HITLAB Announces Inaugural HITLAB Innovators Summit 2HITLAB Announces Inaugural HITLAB Innovators Summit 3Together we are strong -- or insufferable 2Together we are strong -- or insufferable 3Together we are strong -- or insufferable 4
    ... This press release is available in German . ... pathogens and rogue cells in the body and put them out ... migrate from there into the thymus. Here, they mature and differentiate ... Institute of Immunobiology and Epigenetics in Freiburg have now succeeded for ...
    ... Deepwater Horizon oil spill in the Gulf of Mexico in April ... fisheries. A new study published in the Canadian Journal of ... 7 years this oil spill could have a $US8.7 billion impact ... in revenue, profit, and wages, and close to 22 000 jobs ...
    ... The understanding of diseases such as Parkinson,s and Alzheimer,s ... technology at which will enable cell analysis using automated ... School of Information Communication Technology and the Eskitis Institute ... the automated identification, separation and analysis of cells as ...
    Cached Biology News:Live from the thymus: T-cells on the move 2Live from the thymus: T-cells on the move 3
    ... DNA Polymerase I Large (Klenow) Fragment, Exonuclease ... lacks both the 5´→3´ and the 3´→5´ ... DNA Polymerase I (1,2). It is used ... strand displacement amplification (5). Klenow Fragment, Exonuclease ...
    SMVT (N-14)...
    ...
    ... Rabbit polyclonal to Dideoxycytidine Dideoxycytidine is a ... effective in inhibiting retroviral activity. Immunogen: ... Specificity: The specificity of the ... of the moles of ddC to moles of ...
    Biology Products: